Table 4:

Results for health outcomes at 3 years, by tertiles of Frequency of Use Score for cleaning products*

Outcome phenotypeOR (95% CI)Sex FUS
p value
Trend
p value
Overall sample population
n = 2022
Boys
n = 1047
Girls
n = 975
Unadj.Adj.Unadj.Adj.Unadj.Adj.Unadj.Adj.
Recurrent wheeze0.02
 Moderate0.97 (0.65–1.45)0.93 (0.61–1.40)1.05 (0.64–1.71)0.96 (0.57–1.60)0.89 (0.43–1.89)0.91 (0.43–1.95)0.470.62
 High1.46 (1.01–2.14)1.26 (0.85–1.88)1.03 (0.63–1.69)0.88 (0.52–1.49)2.52 (1.35–4.94)2.33 (1.20–4.75)0.040.04
Recurrent wheeze and atopy0.02
 Moderate1.14 (0.49–2.73)1.13 (0.47–2.74)1.53 (0.56–4.53)1.43 (0.51–4.36)1.58 (0.31–11.45)1.83 (0.34–13.49)0.270.32
 High2.06 (0.98–4.63)1.76 (0.81–4.06)1.75 (0.66–5.14)1.46 (0.53–4.41)4.45 (1.14–29.38)4.15 (0.97–28.63)0.650.73
Asthma diagnosis0.01
 Moderate1.36 (0.86–2.19)1.34 (0.83–2.17)1.63 (0.92–2.98)1.60 (0.88–2.97)1.00 (0.45–2.29)0.98 (0.43–2.28)0.260.33
 High1.71 (1.09–2.71)1.57 (0.98–2.53)1.53 (0.85–2.83)1.47 (0.80–2.76)2.01 (0.98–4.37)1.79 (0.83–4.07)0.630.67
Atopy0.25
 Moderate0.98 (0.71–1.34)1.05 (0.76–1.45)1.09 (0.72–1.65)1.20 (0.78–1.86)0.76 (0.47–1.23)0.82 (0.50–1.34)0.420.63
 High1.11 (0.81–1.51)1.17 (0.85–1.63)1.12 (0.74–1.69)1.34 (0.86–2.09)1.02 (0.63–1.65)0.94 (0.57–1.57)0.920.88
  • Note: Adj. = adjusted, CI = confidence interval, FUS = Frequecy of Use Score, OR = odds ratio, Unadj. = unadjusted.

  • * We derived all values using multivariable logistic regression models. These regression models used those participants with homes in the low group of FUS as the reference group to which participants from moderate and high households were compared.

  • Models were adjusted for prenatal or early life exposure to tobacco smoke, sex, child’s ethnicity, parental asthma history, household income, city/location, visible mould in the home and pet ownership.

  • For the sex-stratified analysis, we adjusted for all covariates except sex. The p value of the interaction term when included in the regression model for the overall sample is reported.

  • We used a 1-sided Cochran–Armitage test (unadjusted) to evaluate increasing trends by FUS level for each health outcome. For boys (n = 1047), the FUS was less than 27 for the low-use group (n = 331), between 27 and 35 for the moderate-use group (n = 365) and greater than 35 for the high-use group (n = 351). For girls (n = 975), the FUS was less than 26 for the low-use group (n = 295), between 26 and 35 for the moderate-use group (n = 375) and greater than 35 for the high-use group (n = 305).